Drug intelligence / Profile preview

KRIYA-893

Development stage: Preclinical
Lead developer: Kriya Therapeutics
Modality: Gene Therapies
Administration: Intravitreal, Subretinal

Overview

KRIYA-893 is an investigational adeno-associated virus (AAV) gene therapy being developed by Kriya Therapeutics for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The therapy is designed to deliver a functional gene encoding a variant of complement factor H (CFH), a key regulator of the alternative complement pathway. By increasing the expression of CFH in the retina, KRIYA-893 aims to inhibit the overactive complement-mediated inflammation and tissue damage that drive the progression of GA. It is typically administered via intravitreal injection to provide sustained, localized production of the therapeutic protein.

Targets

CFH (Complement factor H)

Beyond the preview

Go deeper on KRIYA-893.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRIYA-893.

Explore the full profile